<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29691835</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1469-493X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Cochrane database of systematic reviews</Title>
          <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rufinamide add-on therapy for refractory epilepsy.</ArticleTitle>
        <Pagination>
          <StartPage>CD011772</StartPage>
          <MedlinePgn>CD011772</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">CD011772</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD011772.pub2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. In this review, we summarised the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication, when used as an add-on treatment for refractory epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children four years of age and older with Lennox-Gastaut syndrome. It is also approved as an add-on treatment for adults and adolescents with focal seizures.</AbstractText>
          <AbstractText Label="OBJECTIVES">To evaluate the efficacy and tolerability of rufinamide when used as an add-on treatment in people with refractory epilepsy.</AbstractText>
          <AbstractText Label="SEARCH METHODS">On 2 October 2017, we searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid, 1946), ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We also contacted the manufacturers of rufinamide and authors in the field to identify any relevant unpublished studies.</AbstractText>
          <AbstractText Label="SELECTION CRITERIA">Randomised, double-blind, placebo-controlled, add-on trials of rufinamide, recruiting people (of any age or gender) with refractory epilepsy.</AbstractText>
          <AbstractText Label="DATA COLLECTION AND ANALYSIS">Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: 50% or greater reduction in seizure frequency (primary outcomes); seizure freedom; treatment withdrawal; and adverse effects (secondary outcomes). Primary analyses were intention-to-treat (ITT) and we presented summary risk ratios (RR) with 95% confidence intervals (CI). We evaluated dose response in regression models. We carried out a risk of bias assessment for each included study using the Cochrane 'Risk of bias' tool and assessed the overall quality of evidence using the GRADE approach, which we presented in a 'Summary of findings' table.</AbstractText>
          <AbstractText Label="MAIN RESULTS">The review included six trials, representing 1759 participants. Four trials (1563 participants) included people with uncontrolled focal seizures. Two trials (196 participants) included established Lennox-Gastaut syndrome. Overall, the age of the adults ranged from 18 to 80 years and the age of the infants ranged from four to 16 years. Baseline phase ranged from 28 to 56 days and double-blind phases from 84 to 96 days. Five of the six included trials described adequate methods of concealment of randomisation and only three described adequate blinding. All analyses were by ITT. Overall, five studies were at low risk of bias, and one had unclear risk of bias due to lack of reported information around study design. All trials were sponsored by the manufacturer of rufinamide, and therefore, were at high risk of funding bias.The overall RR for 50% or greater reduction in seizure frequency was 1.79 (95% CI 1.44 to 2.22; 6 RCTs; moderate-quality evidence) indicating that rufinamide (plus conventional AED) was significantly more effective than placebo (plus conventional AED) in reducing seizure frequency by at least 50%, when added to conventionally used AEDs in people with refractory focal epilepsy. The overall RR for treatment withdrawal (for any reason and due to AED) was 1.83 (95% CI 1.45 to 2.31; 6 RCTs; moderate-quality evidence) showing that rufinamide was significantly more likely to be withdrawn than placebo. In respect of adverse effects, most were significantly more likely to occur in the rufinamide-treated group. The adverse events significantly associated with rufinamide were: headache, dizziness, somnolence, vomiting, nausea, fatigue and diplopia. The RRs of these adverse effects were: headache 1.36 (95% Cl 1.08 to 1.69; 3 RCTs; high-quality evidence); dizziness 2.52 (95% Cl 1.90 to 3.34; 3 RCTs; moderate-quality evidence); somnolence 1.94 (95% Cl 1.44 to 2.61; 6 RCTs; moderate-quality evidence); vomiting 2.95 (95% Cl 1.80 to 4.82; 4 RCTs; low-quality evidence); nausea 1.87 (95% Cl 1.33 to 2.64; 3 RCTs; moderate-quality evidence); fatigue 1.46 (95% Cl 1.08 to 1.97; 3 RCTs; moderate-quality evidence); and diplopia 4.60 (95% Cl 2.53 to 8.38; 3 RCTs; low-quality evidence). There was no important heterogeneity between studies for any of the outcomes. Overall, we assessed the evidence as moderate to low quality, due to potential risk of bias from some studies contributing to the analysis and wide CIs.</AbstractText>
          <AbstractText Label="AUTHORS' CONCLUSIONS">In people with drug-resistant focal epilepsy, rufinamide when used as an add-on treatment was effective in reducing seizure frequency. However, the trials reviewed were of relatively short duration and provided no evidence for the long-term use of rufinamide. In the short term, rufinamide as an add-on was associated with several adverse events. This review focused on the use of rufinamide in drug-resistant focal epilepsy and the results cannot be generalised to add-on treatment for generalised epilepsies. Likewise, no inference can be made about the effects of rufinamide when used as monotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Panebianco</LastName>
            <ForeName>Mariangela</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Clinical Sciences Centre for Research and Education, Lower Lane, Liverpool, UK, L9 7LJ.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prabhakar</LastName>
            <ForeName>Hemanshu</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marson</LastName>
            <ForeName>Anthony G</ForeName>
            <Initials>AG</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>04</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cochrane Database Syst Rev</MedlineTA>
        <NlmUniqueID>100909747</NlmUniqueID>
        <ISSNLinking>1361-6137</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WFW942PR79</RegistryNumber>
          <NameOfSubstance UI="C079703">rufinamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateIn">
          <RefSource>Cochrane Database Syst Rev. 2020 Nov 8;11:CD011772</RefSource>
          <PMID Version="1">33179247</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069279" MajorTopicYN="N">Drug Resistant Epilepsy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>MP: none known. AGM: a consortium of pharmaceutical companies (GSK, Eisai, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC). HP: none known.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29691835</ArticleId>
        <ArticleId IdType="pmc">PMC6494418</ArticleId>
        <ArticleId IdType="doi">10.1002/14651858.CD011772.pub2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References to studies included in this review</Title>
        <Reference>
          <Citation>Biton V, 
Krauss G, 
Vasquez‐Santana B, 
Bibbiani F, 
Mann A, 
Perdomo C, 
et al. 
A randomized, double‐blind, placebo‐controlled, parallel‐group study of rufinamide as adjunctive therapy for refractory partial‐onset seizures. 
Epilepsia 2011;52(2):234‐42. 
[DOI: 10.1111/j.1528-1167.2010.02729.x; PUBMED: 20887365]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2010.02729.x</ArticleId>
            <ArticleId IdType="pubmed">20887365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NCT00334958. 
Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures. 
https://ClinicalTrials.gov/show/NCT003349582006. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Aldenkamp AP, 
Alpherts WCJ. 
The effect of the new antiepileptic drug rufinamide on cognitive functions. 
Epilepsia 2006;47(7):1153‐9. 
[DOI: 10.1111/j.1528-1167.2006.00589.x; ISSN: 0013‐9580; PUBMED: 16886978]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2006.00589.x</ArticleId>
            <ArticleId IdType="pubmed">16886978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, 
Rosenfeld W, 
Vasquez B, 
Sachdeo R, 
Ko D, 
Perdomo C, 
et al. 
Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. 
Epilepsia 2005;46 Suppl 8:171, Abstract no: 2.239. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, 
Rosenfeld W, 
Vazquez B, 
Sachdeo R, 
Perdomo C, 
Mann A, 
et al. 
Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo‐controlled trial. 
Epilepsia 2009;50(8):1899‐909. 
[DOI: 10.1111/j.1528-1167.2009.02160.x; PUBMED: 19490053]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2009.02160.x</ArticleId>
            <ArticleId IdType="pubmed">19490053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld W, 
Brodie M, 
Vazquez B, 
Sachdeo R, 
Ko D, 
Perdomo C, 
et al. 
Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. 
Epilepsia 2006;47 Suppl 3:140, Abstract no: p538. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Vazquez BR, 
Sachdeo R, 
Maxoutova AL, 
Beydoun A, 
Karolchyk MA, 
Mesenbrink PG. 
Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy‐resistant partial‐onset seizures. 
Epilepsia 2000;41 Suppl 7:255, Abstract no: L.09. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Elger C, 
Stefan H, 
Perdomo C, 
Arroyo S. 
Dose‐range relationships of rufinamide in patients with inadequately controlled partial seizures. 
Epilepsia 2005;46 Suppl 8:83‐4, Abstract no: 1.201. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Elger C, 
Stefan H, 
Perdomo C, 
Arroyo S. 
Dose‐range relationships of rufinamide in patients with inadequately controlled partial seizures. 
Epilepsia 2006;47 Suppl 3:140, Abstract no: p539. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Elger CE, 
Stefan H, 
Mann A, 
Narurkar M, 
Sun Y, 
Perdomo C. 
A 24‐week multicenter, randomized, double‐blind, parallel‐group, dose ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. 
Epilepsy Research 2010;88(2‐3):255‐63. 
[DOI: 10.1016/j.eplepsyres.2009.12.003; PUBMED: 20061123]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2009.12.003</ArticleId>
            <ArticleId IdType="pubmed">20061123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefan H, 
Remy C, 
Guberman A, 
Thomson A, 
Arbelaiz R, 
Karolchyk MA. 
A multicenter double‐blind randomized placebo‐controlled 5‐arm, parallel‐group trial of rufinamide in patients with therapy‐resistant partial seizures. 
Epilepsia 2000;41 Suppl Florence:39. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Arzimanoglou A, 
Litzinger M, 
Frank LM, 
Vigevano F, 
Perdomo C. 
Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients. 
Epilepsia 2005;46 Suppl 8:194‐5. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Kluger G, 
Krauss G, 
Arroyo S. 
Effects of rufinamide on the frequency of different seizure types in patients with Lennox‐Gastaut syndrome: a long‐term study. 
Epilepsia 2007;48 Suppl 7:156, Abstract no: p415. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Kluger G, 
Sachdeo R, 
Krauss G, 
Perdomo C, 
Arroyo S. 
Rufinamide for generalized seizures associated with Lennox‐Gastaut Syndrome. 
Neurology 2008;70(21):1950‐8. 
[DOI: 10.1212/01.wnl.0000303813.95800.0d; PUBMED: 18401024]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000303813.95800.0d</ArticleId>
            <ArticleId IdType="pubmed">18401024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Kluger G, 
Sachdeo R, 
Krauss G, 
Perdomo C, 
Arroyo S. 
Short‐term and long‐term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox‐Gastaut syndrome. 
Annals of neurology 2005;58 Suppl 9:S92, Abstract no: M15. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Kluger G, 
Sachedo R, 
Krauss G, 
Perdomo C, 
Arroyo S. 
Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox‐Gastaut syndrome (LGS): a multicenter, randomized, double‐blind, placebo‐controlled, parallel trial. 
Neurology 2005;64(10):1826, Abstract no: LBS.001. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Santana BV, 
Wang W, 
Narurkar M. 
Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox‐Gastaut syndrome. 
Epilepsia 2009;50 Suppl 11:261, Abstract no: 2.229. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Kluger G, 
Glauser T, 
Sachdeo R, 
Krauss G, 
Perdomo C, 
Arroyo S. 
Short‐term and long‐term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox‐Gastaut syndrome. 
Epilepsia 2006;47 Suppl 3:139, Abstract no: p537. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Krauss GL, 
Glauser T, 
Kluger G, 
Arroyo S. 
Long‐term safety of rufinamide in patients with Lennox‐Gastaut syndrome. 
Epilepsia 2007;48 Suppl 6:359, Abstract no: 3.303. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMurray R, 
Striano P. 
Treatment of Adults with Lennox‐Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide. 
Neurology &amp; Therapy 2016;5(1):35‐43. 
[DOI: 10.1007/s40120-016-0041-9; ISSN: 2193‐8253 2193‐6536; PUBMED: 26861566]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40120-016-0041-9</ArticleId>
            <ArticleId IdType="pmc">PMC4919131</ArticleId>
            <ArticleId IdType="pubmed">26861566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NCT01146951. 
A Placebo‐Controlled, Double‐Blind Comparative Study of E2080 in Lennox‐Gastaut Syndrome Patients (Study E2080‐J081‐304). 
https://ClinicalTrials.gov/show/NCT011469512010. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Ohtsuka Y, 
Yoshinaga H, 
Shirasaka Y, 
Takayama R, 
Takano H, 
Iyoda K. 
Long‐term safety and seizure outcome in Japanese patients with Lennox‐Gastaut syndrome receiving adjunctive rufinamide therapy: An open‐label study following a randomized clinical trial. 
Epilepsy Research 2016;121:1‐7. 
[DOI: 10.1016/j.eplepsyres.2016.01.002; PUBMED: 26827266]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2016.01.002</ArticleId>
            <ArticleId IdType="pubmed">26827266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohtsuka Y, 
Yoshinaga H, 
Shirasaka Y, 
Takayama R, 
Takano H, 
Iyoda K. 
Rufinamide as an adjunctive therapy for Lennox‐Gastaut syndrome: a randomized double‐blind placebo‐controlled trial in Japan. 
Epilepsy Research 2014;108(9):1627‐36. 
[DOI: 10.1016/j.eplepsyres.2014.08.019; PUBMED: 25219353]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2014.08.019</ArticleId>
            <ArticleId IdType="pubmed">25219353</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>References to studies excluded from this review</Title>
        <Reference>
          <Citation>Benedict A, 
Verdian L, 
Maclaine G. 
The cost effectiveness of rufinamide in the treatment of Lennox‐Gastaut syndrome in the UK. 
Pharmacoeconomics 2010;28(3):185‐99. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20151724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biton V, 
Sachdeo R, 
Rosenfeld W, 
Schachter S, 
Perdomo C, 
Arroyo S. 
Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalized tonic‐clonic seizures. 
Epilepsia 2005;46(8):206. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Critchley D, 
Fuseau E, 
Perdomo C, 
Arroyo S. 
Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox‐Gastaut syndrome. 
Epilepsia 2005;46 Suppl 8:209. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Kim SH, 
Eun SH, 
Kang HC, 
Kwon EJ, 
Byeon JH, 
Lee YM. 
Rufinamide as an adjuvant treatment in children with Lennox‐Gastaut syndrome. 
Seizure 2012;21(4):288‐91. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22421185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluger G, 
Bauer B. 
Role of rufinamide in the management of Lennox‐Gastaut syndrome (childhood epileptic encephalopathy). 
Neuropsychiatric Disease &amp; Treatment 2007;3(1):3‐11. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2654531</ArticleId>
            <ArticleId IdType="pubmed">19300535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knupp KG, 
Leister E, 
Coryell J, 
Nickels KC, 
Ryan N, 
Juarez‐Colunga E, 
et al. 
Pediatric Epilepsy Research Consortium. 
Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. 
Epilepsia 2016;57(11):1834‐42. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5863234</ArticleId>
            <ArticleId IdType="pubmed">27615012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesser RP, 
Biton V, 
Sackellares JC, 
Ness PC, 
Perdomo C, 
Arroyo S. 
Efficacy and safety of rufinamide monotherapy for treatment of patients with refractory partial seizures. 
Epilepsia 2005;46 Suppl 8:177‐8. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Madeddu F, 
Moavero R, 
Battaglia D, 
Matricardi S, 
Coppola G, 
Balestri M. 
Efficacy of rufinamide in epileptic encephalopathies secondary to complex brain malformations. 
Bollettino ‐ Lega Italiana Contro l'Epilessia 2013;145:278‐80. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Palhagen S, 
Canger R, 
Henriksen O, 
Parys JA, 
Riviere ME, 
Karolchyk MA. 
Rufinamide: a double‐blind, placebo‐controlled proof of principle trial in patients with epilepsy. 
Epilepsy Research 2001;43(2):115‐24. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11164700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Racine A, 
Rouan MC, 
Chang SW, 
Yeh CM, 
Karolchyk MA. 
Population pharmacokinetics and drug‐drug interactions of rufinamide in a multicenter, double‐blind, randomized, placebo‐controlled, 5‐arm parallel trial in patients with partial seizures on up to three concomitant antiepileptic drugs. 
Epilepsia 2000;41 Suppl:149‐50. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Todorov A, 
Biton V, 
Krauss GL, 
Perdomo C, 
Arroyo S. 
Efficacy and safety of high‐versus low‐dose rufinamide monotherapy in patients with inadequately controlled partial seizures. 
Epilepsia 2005;46 Suppl 8:218‐9. 
</Citation>
        </Reference>
        <Reference>
          <Citation>Xu M, 
Ni Y, 
Zhou Y, 
He X, 
Li H, 
Chen H. 
Pharmacokinetics and tolerability of rufinamide following single and multiple oral doses and effect of food on pharmacokinetics in healthy Chinese subjects. 
European Journal of Drug Metabolism and Pharmacokinetics 2016;41(5):541‐8. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26294172</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>References to ongoing studies</Title>
        <Reference>
          <Citation>Arzimanoglou A, 
Ferreira JA, 
Satlin A, 
Mendes S, 
Williams B, 
Critchley D, 
et al. 
Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox‐Gastaut syndrome: an interim analysis from a multicenter, randomized, active‐controlled, open‐label study. 
European Journal of Paediatric Neurology: EJPN 2016;20(3):393‐402. 
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26805435</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>Additional references</Title>
        <Reference>
          <Citation>Aldenkamp AP, 
Alpherts WCJ. 
The effect of the new antiepileptic drug rufinamide on cognitive functions. 
Epilepsia 2006;47(7):1153‐9.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16886978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, 
Rosenfels W, 
Vasquez B, 
Sachdeo R, 
Perdomo C. 
Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. 
Epilepsia 2005;46 Suppl 8:171.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppola G. 
Update on rufinamide in childhood epilepsy. 
Neuropsychiatric Disease and Treatment 2011;7:399‐407.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3140292</ArticleId>
            <ArticleId IdType="pubmed">21792306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elger C, 
Stefan H, 
Perdomo C, 
Arroyo S. 
Dose‐range relationships of rufinamide in patients with inadequately controlled partial seizures. 
Epilepsia 2005;46 Suppl 8:83‐4.
</Citation>
        </Reference>
        <Reference>
          <Citation>Elger C, 
Stefan H, 
Perdomo C, 
Arroyo S. 
Dose‐range relationships of rufinamide in patients with inadequately controlled partial seizures. 
Epilepsia 2006;47 Suppl 3:140.
</Citation>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Kluger G, 
Krauss G, 
Arroyo S. 
Effects of rufinamide on the frequency of different seizure types in patients with Lennox‐Gastaut syndrome: a long‐term study. 
Epilepsia 2007;48 Suppl 7:156.
</Citation>
        </Reference>
        <Reference>
          <Citation>Glauser T, 
Santana BV, 
Wang W, 
Narurkar M. 
Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox‐Gastaut syndrome. 
Epilepsia 2009;50 Suppl 11:261.
</Citation>
        </Reference>
        <Reference>
          <Citation>Granata T, 
Marchi N, 
Carlton E, 
Chosh C, 
Gonzalez‐Martinez J, 
Alexopoulous A, 
et al. 
Management of the patient with medically refractory epilepsy. 
Expert Review of Neurotherapeutics 2009;9(12):1791‐802.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3761964</ArticleId>
            <ArticleId IdType="pubmed">19951138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guyatt GH, 
Oxman AD, 
Vist G, 
Kunz R, 
Falck‐Ytter Y, 
Alonso‐Coello P, 
et al. 
the GRADE Working Group. 
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. 
BMJ 2008;336(7650):924‐6.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2335261</ArticleId>
            <ArticleId IdType="pubmed">18436948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, 
Green S, 
editor(s). 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. 
Available from handbook.cochrane.org.
</Citation>
        </Reference>
        <Reference>
          <Citation>Hsieh DT, 
Thiele EA. 
Efficacy and safety of rufinamide in pediatric epilepsy. 
Therapeutic Advances in Neurological Disorders 2013;6(3):189‐98.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3625016</ArticleId>
            <ArticleId IdType="pubmed">23634191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ILAE Commission on Epidemiology and Prognosis. 
Guidelines for epidemiologic studies on epilepsy. 
Epilepsia 1993;34:592‐6.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8330566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirkham JJ, 
Dwan KM, 
Altman DG, 
Gamble C, 
Dodd S, 
Smyth R, 
et al. 
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. 
BMJ 2010;340:c365.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20156912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluger G, 
Glauser T, 
Sachdeo R, 
Krauss G, 
Perdomo C, 
Arroyo S. 
Short‐term and long‐term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox‐Gastaut syndrome. 
Epilepsia 2006;47 Suppl 3:139.
</Citation>
        </Reference>
        <Reference>
          <Citation>Krauss GL, 
Glauser T, 
Kluger G, 
Arroyo S. 
Long‐term safety of rufinamide in patients with Lennox‐Gastaut syndrome. 
Epilepsia 2007;48 Suppl 6:359.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefebvre C, 
Manheimer E, 
Glanville J. 
Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. 
Available from handbook.cochrane.org.
</Citation>
        </Reference>
        <Reference>
          <Citation>McMurray R, 
Striano P. 
Treatment of adults with Lennox‐Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. 
Neurology and Therapy 2016;5(1):35‐43.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4919131</ArticleId>
            <ArticleId IdType="pubmed">26861566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bibbiani F. 
Rufinamide given as adjunctive therapy in patients with refractory partial seizures. 
clinicaltrials.gov/show/NCT00334958 Date first registered: 8 June 2006.
</Citation>
        </Reference>
        <Reference>
          <Citation>Takano H. 
A placebo‐controlled, double‐blind comparative study of E2080 in Lennox‐Gastaut syndrome patients. 
clinicaltrials.gov/show/NCT01146951 Date first registered: 22 June 2010.
</Citation>
        </Reference>
        <Reference>
          <Citation>Ohtsuka Y, 
Yoshinaga H, 
Shirasaka Y, 
Takayama R, 
Takano H, 
Iyoda K. 
Long‐term safety and seizure outcome in Japanese patients with Lennox‐Gastaut syndrome receiving adjunctive rufinamide therapy: an open‐label study following a randomized clinical trial. 
Epilepsy Research 2016;121:1‐7.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26827266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panebianco M, 
Rigby A, 
Marson AG, 
Pulman J. 
Vagus nerve stimulation for partial seizures. 
Cochrane Database of Systematic Reviews 2015, Issue 4. 
[DOI: 10.1002/14651858.CD002896.pub2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD002896.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC7138043</ArticleId>
            <ArticleId IdType="pubmed">25835947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld W, 
Brodie M, 
Vazquez B, 
Sachdeo R, 
Ko D, 
Perdomo C. 
Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. 
Epilepsia 2006;47 Suppl 3:140.
</Citation>
        </Reference>
        <Reference>
          <Citation>Stefan H, 
Remy C, 
Guberman A, 
Thomson A, 
Arbelaiz R, 
Karolchyk MA. 
A multicenter double‐blind randomized placebo‐controlled 5‐arms, parallel‐group trial of rufinamide in patients with therapy‐resistant partial seizures. 
Epilepsia 2000;41(Suppl):39.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne JA, 
Gavaghan D, 
Egger M. 
Publication and related bias in meta‐analysis: power of statistical tests and prevalence in literature. 
Journal of Clinical Epidemiology 2000;53(11):1119‐29.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11106885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Striano P, 
McMurray R. 
Rufinamide as adjunctive treatment for adults with Lennox‐Gastaut syndrome: subgroup analysis from a phase III trial. 
Epilepsia 2015;56(Suppl 1):211.
</Citation>
        </Reference>
        <Reference>
          <Citation>Vazquez BR, 
Sachdeo R, 
Maxoutova AL, 
Beydoun A, 
Karolchyk MA, 
Mesenbrink PG. 
Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy‐resistant partial‐onset seizures. 
Epilepsia 2000;41(Suppl 7):255.
</Citation>
        </Reference>
        <Reference>
          <Citation>Wheless J, 
Conry J, 
Krauss G, 
Mann A, 
LoPresti A, 
Narurkar M. 
Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of seven clinical trials. 
Journal of Child Neurology 2009;50:1158‐66.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19955344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheless JW, 
Vazquez B. 
Rufinamide: a novel broad‐spectrum antiepileptic drug. 
Epilepsy Currents 2010;10(1):1‐6.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2812713</ArticleId>
            <ArticleId IdType="pubmed">20126329</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>References to other published versions of this review</Title>
        <Reference>
          <Citation>Panebianco M, 
Marson AG. 
Rufinamide add‐on therapy for refractory epilepsy. 
Cochrane Database of Systematic Reviews 2015, Issue 6. 
[DOI: 10.1002/14651858.CD011772]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD011772</ArticleId>
            <ArticleId IdType="pmc">PMC6494418</ArticleId>
            <ArticleId IdType="pubmed">29691835</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
